These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18642543)

  • 1. Gaining ground on breast cancer.
    Esteva FJ; Hortobagyi GN
    Sci Am; 2008 Jun; 298(6):58-65. PubMed ID: 18642543
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic targeting in breast cancer].
    Penault-Llorca F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
    [No Abstract]   [Full Text] [Related]  

  • 3. Ten years of HER2-directed therapy: still questions after all these years.
    Krop IE; Winer EP
    Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
    Campos SM
    Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
    Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The breast cancer panel: a case-based discussion on the use of targeted therapies for primary and metastatic disease.
    Fortenbaugh C
    ONS News; 2006; 21(8 Suppl):37-8. PubMed ID: 16925144
    [No Abstract]   [Full Text] [Related]  

  • 9. HER2 Intermediate Breast Cancers.
    Jensen KC; Nielsen TO; Gilks CB; West RB
    Am J Surg Pathol; 2009 Nov; 33(11):1739; author reply 1739-40. PubMed ID: 19745698
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
    Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
    Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Her2 positive breast cancer: practices].
    Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
    Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.
    Ravdin PM; Chamness GC
    Gene; 1995 Jun; 159(1):19-27. PubMed ID: 7607568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
    Chandarlapaty S; Modi S
    J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
    [No Abstract]   [Full Text] [Related]  

  • 16. Should we treat HER, too?
    Hayes DF
    J Clin Oncol; 1996 Mar; 14(3):697-9. PubMed ID: 8622013
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systemic treatment of brain metastases from breast cancer].
    Taillibert S; Conforti R; Bonneterre J; Bachelot T; Le Rhun E; Bernard-Marty C
    Cancer Radiother; 2015 Feb; 19(1):36-42. PubMed ID: 25662600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple negative breast cancer: a brief review of its characteristics and treatment options.
    Griffiths CL; Olin JL
    J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herceptin: breaking new ground.
    Cohen RL
    Cancer Biother Radiopharm; 1999 Feb; 14(1):1-4. PubMed ID: 10850280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.